JP2009523841A - 一酸化炭素の治療的供給 - Google Patents

一酸化炭素の治療的供給 Download PDF

Info

Publication number
JP2009523841A
JP2009523841A JP2008551859A JP2008551859A JP2009523841A JP 2009523841 A JP2009523841 A JP 2009523841A JP 2008551859 A JP2008551859 A JP 2008551859A JP 2008551859 A JP2008551859 A JP 2008551859A JP 2009523841 A JP2009523841 A JP 2009523841A
Authority
JP
Japan
Prior art keywords
alkyl
aryl
group
pharmaceutical composition
alk
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008551859A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009523841A5 (enExample
Inventor
モッテリーニ、ロベルト、アンジェロ
マン、ブライアン、アーネスト
ジョンソン、トニー、リチャード
スケイペンス、デビッド、アリステア
アキル、リーハン
ペリエ、トレバー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hemocorm Ltd
Original Assignee
Hemocorm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hemocorm Ltd filed Critical Hemocorm Ltd
Publication of JP2009523841A publication Critical patent/JP2009523841A/ja
Publication of JP2009523841A5 publication Critical patent/JP2009523841A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2008551859A 2006-01-24 2007-01-23 一酸化炭素の治療的供給 Pending JP2009523841A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0601394.0A GB0601394D0 (en) 2006-01-24 2006-01-24 Therapeutic delivery of carbon monoxide
PCT/GB2007/000198 WO2007085806A2 (en) 2006-01-24 2007-01-23 Therapeutic delivery of carbon monoxide

Publications (2)

Publication Number Publication Date
JP2009523841A true JP2009523841A (ja) 2009-06-25
JP2009523841A5 JP2009523841A5 (enExample) 2010-03-11

Family

ID=36010856

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008551859A Pending JP2009523841A (ja) 2006-01-24 2007-01-23 一酸化炭素の治療的供給

Country Status (6)

Country Link
US (1) US8389572B2 (enExample)
EP (1) EP1978952A2 (enExample)
JP (1) JP2009523841A (enExample)
CN (1) CN101466372A (enExample)
GB (1) GB0601394D0 (enExample)
WO (1) WO2007085806A2 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0111872D0 (en) 2001-05-15 2001-07-04 Northwick Park Inst For Medica Therapeutic agents and methods
US7011854B2 (en) 2002-02-04 2006-03-14 Alfama-Investigacao e Desenvolvimento de Produtos Farmaceuticos Lda Method for treating a mammal by administration of a compound having the ability to release CO, compounds having the ability to release CO and pharmaceutical compositions thereof
US7968605B2 (en) 2002-02-04 2011-06-28 ALFAMA—Investigação e Desenvolvimento de Produtos Farmacêuticos, Lda. Methods for treating inflammatory disease by administering aldehydes and derivatives thereof
GB2395432B (en) 2002-11-20 2005-09-14 Northwick Park Inst For Medica Therapeutic delivery of carbon monoxide to extracorporeal and isolated organs
US20070207217A1 (en) * 2003-02-03 2007-09-06 Alfama - Investigacao E Desenvolvimento De Productos Farmaceuticos Lda Method for treating a mammal by administration of a compound having the ability to release CO
CA2534415A1 (en) * 2003-08-04 2005-02-17 Northwick Park Institute For Medical Research Therapeutic delivery of carbon monoxide
GB0601394D0 (en) 2006-01-24 2006-03-01 Hemocorm Ltd Therapeutic delivery of carbon monoxide
GB0613362D0 (en) * 2006-07-05 2006-08-16 Hemocorm Ltd Therapeutic delivery of carbon monoxide
EP2148688A1 (en) * 2007-04-24 2010-02-03 Alfama - Investigaçao e Desenvolvimento de Productos Farmaceuticos LDA. Treatment of infections by carbon monoxide
WO2009013612A1 (en) * 2007-07-24 2009-01-29 Alfama - Investigação E Desenvolvimento De Produtos Farmacêuticos, Lda. Prevention of gastric ulcery by carbon monoxide
US8697747B2 (en) 2009-03-05 2014-04-15 The Uab Research Foundation Enhancing coagulation or reducing fibrinolysis
JP2011152261A (ja) * 2010-01-27 2011-08-11 Nippon Koden Corp 携帯型生体信号測定・送信システム
US8927750B2 (en) 2011-02-04 2015-01-06 Universitaet Zu Koeln Acyloxy- and phosphoryloxy-butadiene-Fe(CO)3 complexes as enzyme-triggered co-releasing molecules
JP5978291B2 (ja) 2011-04-19 2016-08-24 アルファーマ インコーポレイテッドＡｌｆａｍａ，Ｉｎｃ． 一酸化炭素放出分子およびその使用
PL216649B1 (pl) * 2011-06-06 2014-04-30 Univ Warszawski Nowe kompleksy rutenu, sposób ich wytwarzania oraz zastosowanie w reakcji metatezy olefin
JP6134710B2 (ja) 2011-07-21 2017-05-24 アルファーマ インコーポレイテッドＡｌｆａｍａ，Ｉｎｃ． 一酸化ルテニウム放出分子およびその使用
DE102012004132A1 (de) * 2012-02-29 2013-08-29 Friedrich-Schiller-Universität Jena Kohlenstoffmonoxid freisetzende Materialien und deren Verwendung
US20150173674A1 (en) * 2013-12-20 2015-06-25 Diabetes Sentry Products Inc. Detecting and communicating health conditions
DE102014008685A1 (de) 2014-06-13 2015-12-17 Lorenz Meinel Freisetzungssystem für therapeutisches Gas
US10881314B2 (en) * 2014-12-30 2021-01-05 General Electric Company Common display unit for a plurality of cableless medical sensors
WO2017007955A1 (en) 2015-07-07 2017-01-12 The Research Foundation For The State University Of New York Use of amine carboxyboranes as therapeutic delivery of carbon monoxide and as general drug delivery system in the presence of reactive oxygen species
WO2017027810A2 (en) 2015-08-12 2017-02-16 The General Hospital Corporation Compositions and methods that promote hypoxia or the hypoxia response for treatment and prevention of mitochondrial dysfunction and oxidative stress disorders
JP6796772B2 (ja) * 2016-08-23 2020-12-09 パナソニックＩｐマネジメント株式会社 運動テスト評価システム、運動テスト評価装置、運動テスト評価方法及びコンピュータプログラム

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004532244A (ja) * 2001-05-15 2004-10-21 ノースウィック パーク インスティテュート フォー メディカル リサーチ 一酸化炭素の治療目的での放出
JP2004533427A (ja) * 2001-04-07 2004-11-04 ウニヴェルジテートスクリニクム シャリーテ 高度増殖細胞によって引き起こされる疾病の治療のための物質
JP2005519928A (ja) * 2002-02-04 2005-07-07 ハース，ベルナー Ｃｏ放出能力を有する化合物の投与によって哺乳動物を治療する方法と、ｃｏ放出能力を有する化合物ならびにその医薬組成物

Family Cites Families (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2870180A (en) 1955-10-13 1959-01-20 Ethyl Corp Process for the preparation of hydrocarbon manganese carbonyl compounds
US3278570A (en) 1961-04-11 1966-10-11 Ethyl Corp Molybdenum pentacarbonyl compounds and process for preparing same
US3452079A (en) 1964-06-15 1969-06-24 Merck & Co Inc Acetic acid type compounds
GB1118728A (en) 1966-04-28 1968-07-03 James Kaye Improvements in or relating to the shaping of thermoplastic sheeting
CH536294A (de) 1968-09-13 1973-04-30 Schering Ag Verfahren zur Herstellung von racemischen und optisch aktiven 4,6-Dichlor-4,6-östradienen
US3829504A (en) 1970-06-04 1974-08-13 Int Flavors & Fragrances Inc Novel di-lower alkyl and lower alkylene acetals of 2-and 3-phenyl-pentenals
US3694232A (en) 1970-06-04 1972-09-26 Int Flavors & Fragrances Inc Flavoring methods and compositions containing 3-phenyl pentenals
US3980583A (en) 1974-02-19 1976-09-14 Mobil Oil Corporation Complexed metals bonded to inorganic oxides
NL7802482A (nl) 1977-03-17 1978-09-19 Klosa Josef Preparaat voor de profylaxis en therapie van acne vulgaris en werkwijze voor de profylaxis en therapie van acne vulgaris met behulp van pyridinaldehyden.
US4312989A (en) 1979-08-21 1982-01-26 The United States Of America As Represented By The Secretary Of The Army Pharmacologically active amine boranes
EP0034238B1 (en) 1979-12-21 1985-04-17 Duke University Pharmacologically active amine-carboxyboranes
US4322411A (en) 1980-04-25 1982-03-30 Burroughs Wellcome Co. Anti-inflammatory nucleosides
US4613621A (en) 1981-09-18 1986-09-23 Hoerrmann Wilhelm Fatty aldehydes and acids in the treatment of neurological and inflammatory diseases
DE3139358C2 (de) 1981-10-02 1984-06-07 Dragoco Gerberding & Co Gmbh, 3450 Holzminden Verwendung von 1,1-Di(C↓1↓-C↓6↓-alkyl)-2-phenyl-ethan-Derivaten als Riechstoffe
US4535167A (en) 1981-12-14 1985-08-13 Merck & Co. Inc. Chiral, N-protected, N-substituted α-amino acids
US4649151A (en) 1982-09-27 1987-03-10 Health Research, Inc. Drugs comprising porphyrins
GB8407557D0 (en) 1984-03-23 1984-05-02 Hayward J A Polymeric lipsomes
US4647555A (en) 1984-10-25 1987-03-03 The United States Of America As Represented By The Secretary Of The Army Esters of boron analogues of amino acids
US4657902A (en) 1985-03-25 1987-04-14 The Rockefeller University Therapeutic use of tin mesoporphyrin
US4709083A (en) 1986-05-19 1987-11-24 The United States Of America As Represented By The Secretary Of The Army Method of making boron analogues
US4668670A (en) 1986-06-20 1987-05-26 The Rockefeller University Tin diiododeuteroporphyrin and therapeutic use thereof
US4699903A (en) 1986-06-20 1987-10-13 The Rockefeller University Therapeutic use of tin diiododeuteroporphyrin
JPH0670025B2 (ja) 1987-08-07 1994-09-07 鐘紡株式会社 ベンゾチアゾ−ル誘導体および該化合物を有効成分とする抗リウマチ剤
US5350767A (en) 1987-11-19 1994-09-27 Aktiebolaget Draco Derivatives of cysteine
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
US5086060A (en) 1989-07-25 1992-02-04 Eastman Kodak Company Compound and method for treating skin for acne or psoriasis
US5010073A (en) 1989-10-05 1991-04-23 The Rockefeller University Use of liposomes as carriers for metalloporphyrins
US5362732A (en) 1989-12-20 1994-11-08 University Of North Carolina At Chapel Hill Boronated compounds
HU211084B (en) 1990-04-20 1995-10-30 Brezo Process for producing oral pharmaceutical composition of bone strengthening activity
DE4014762A1 (de) 1990-05-05 1991-11-07 Martin Prof Dr Wenzel Verbindungen zur strahlentherapie oder diagnostik durch absorption von moessbauer-strahlung
US5102670A (en) 1990-09-14 1992-04-07 Abraham Nader G Method for treating eye disorders by reducing 12(r)-hydroxyeicosatetraenoic acid and 12(r)-dihydroxyeicosatrienoic acid levels
US5254706A (en) 1991-05-10 1993-10-19 Boron Biologicals, Inc. Process of making phosphite-borane compounds
EP0746324A1 (en) 1991-09-13 1996-12-11 Boron Biologicals, Inc. Method of combatting osteoporosis and other disease states in mammalian subjects, utilizing organic boron compounds
GB2271351A (en) 1992-10-08 1994-04-13 Merck Patent Gmbh Carbocyclyl-phenyl-pyrazines and liquid crystalline media
GB9221327D0 (en) 1992-10-10 1992-11-25 Harden Richard C Letter receptacle
IT1256450B (it) 1992-11-26 1995-12-05 Soldato Piero Del Esteri nitrici con attivita' farmacologica e procedimento per la loro preparazione
FR2707085B1 (fr) 1993-06-30 1995-08-18 Adir Nouveaux dérivés d'alpha amino acides, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
GB9317686D0 (en) 1993-08-25 1993-10-13 Johnson Matthey Plc Pharmaceutical compositions
US6417182B1 (en) 1993-08-25 2002-07-09 Anormed Inc. Pharmaceutical compositions comprising metal complexes
US6284752B1 (en) 1993-08-25 2001-09-04 Anormed Inc. Pharmaceutical compositions comprising metal complexes
US5811463A (en) 1993-10-06 1998-09-22 University Of British Columbia Compositions and method for relaxing smooth muscles
US5700947A (en) 1993-10-06 1997-12-23 Nicox S.A. Nitric esters having anti-inflammatory and/or analgesic activity and process for their preparation
US5631284A (en) 1993-10-06 1997-05-20 University Of British Columbia Compositions and methods for relaxing smooth muscles
US6051576A (en) 1994-01-28 2000-04-18 University Of Kentucky Research Foundation Means to achieve sustained release of synergistic drugs by conjugation
US5891689A (en) 1994-04-12 1999-04-06 Innovir Laboratories, Inc. Heme-bearing microparticles for targeted delivery of drugs
WO1995030641A1 (en) 1994-05-10 1995-11-16 Nicox S.A. Nitro compounds and their compositions having anti-inflammatory, analgesic and anti-thrombotic acitivities
DE4421433C1 (de) 1994-06-18 1995-06-08 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit Wirkstoffen, die Kohlenmonoxid-Quellen darstellen, Verfahren zu seiner Herstellung und seine Verwendung
US5801184A (en) 1994-07-25 1998-09-01 Glasky; Alvin J. Carbon monoxide dependent guanylyl cyclase modifiers and methods of use
US5447939A (en) 1994-07-25 1995-09-05 Glasky; Alvin J. Carbon monoxide dependent guanylyl cyclase modifiers and methods of use
NZ291592A (en) 1994-07-25 2001-03-30 Michel P Rathbone Use of carbon monoxide dependent guanylyl cyclase modulating purine derivative for treating neurological diseases
US6338963B1 (en) 1994-07-25 2002-01-15 Neotherapeutics, Inc. Use of carbon monoxide dependent guanylyl cyclase modifiers to stimulate neuritogenesis
US6066333A (en) 1994-09-22 2000-05-23 William Harvey Research Limited Pharmaceutical control of inflammation
US5664563A (en) 1994-12-09 1997-09-09 Cardiopulmonary Corporation Pneumatic system
US5670664A (en) 1995-09-08 1997-09-23 University Of Maryland Biotechnology Institute Photosensitive organic compounds that release carbon monoxide upon illumination
DE19540475A1 (de) 1995-10-20 1997-04-24 Schering Ag Chirale Methylphenyloxazolidinone
US5767157A (en) 1996-01-16 1998-06-16 Van Moerkerken; Arthur Arthritic pain prevention method and compositions
IT1276071B1 (it) 1995-10-31 1997-10-24 Nicox Ltd Compositi ad attivita' anti-infiammatoria
US20020193363A1 (en) 1996-02-26 2002-12-19 Bridger Gary J. Use of nitric oxide scavengers to modulate inflammation and matrix metalloproteinase activity
DE69734983T2 (de) 1996-03-20 2006-09-07 President And Fellows Of Harvard College, Cambridge Triarylmethanverbindungen zur behandlung von krebs, aktinischer keratose und kaposisarkom
US5888982A (en) 1996-04-01 1999-03-30 President And Fellows Of Harvard College Regulation of vascular smooth muscle cell heme oxygenase-1
BR9708601A (pt) 1996-04-05 1999-08-03 Gen Hospital Corp Tratamento de uma hemoglobinopatia
US5756492A (en) 1996-09-09 1998-05-26 Sangstat Medical Corporation Graft survival prolongation with porphyrins
US8128963B2 (en) 1996-09-27 2012-03-06 The Trustees Of Columbia University In The City Of New York Methods for treating ischemic disorders using carbon monoxide
IT1295694B1 (it) 1996-11-14 1999-05-27 Nicox Sa Nitrossi derivati per la preparazione di medicamenti ad attivita antitrombinica
US6344178B1 (en) 1997-04-25 2002-02-05 Mallinckrodt Inc. Method for the preparation of facial metal tricarbonyl compounds and their use in the labelling of biologically active substrates
IT1292377B1 (it) 1997-06-19 1999-02-08 Nicox Sa Composizioni farmaceutiche a base di prostaglandine
IT1292426B1 (it) 1997-06-27 1999-02-08 Nicox Sa Sali nitrati di ace-inibitori
US6203991B1 (en) 1998-08-21 2001-03-20 The Regents Of The University Of Michigan Inhibition of smooth muscle cell migration by heme oxygenase I
WO2000021965A1 (en) 1998-10-13 2000-04-20 Brown University Research Foundation Substituted perhalogenated phthalocyanines
BR9915539A (pt) 1998-10-23 2001-10-16 Procter & Gamble Pró-accord de fragrância e bibliotecas de fragrância de aldeìdo e cetona
AU2366900A (en) 1998-12-17 2000-07-03 Sangstat Medical Corporation Methods for enhancing graft survival by modulating heme oxygenase activity
US6025394A (en) 1999-01-29 2000-02-15 Cell Pathways, Inc. Method for treating patients with acne by administering substituted sulfonyl indenyl acetic acids, amides and alcohols
US6673908B1 (en) 1999-02-22 2004-01-06 Nuvelo, Inc. Tumor necrosis factor receptor 2
MXPA01009410A (es) 1999-03-19 2003-06-06 Anormed Inc Composiciones farmaceuticas que comprenden complejos de metal.
US7678390B2 (en) 1999-04-01 2010-03-16 Yale University Carbon monoxide as a biomarker and therapeutic agent
US6251927B1 (en) 1999-04-20 2001-06-26 Medinox, Inc. Methods for treatment of sickle cell anemia
ATE420093T1 (de) 1999-10-05 2009-01-15 Mallinckrodt Inc Carbonmonoxidquelle für die herstellung von übergangsmetallcarbonylkomplexe
US6484747B2 (en) 2000-04-05 2002-11-26 Jerry S. Bridgers Medical gas utility stand
US6518269B1 (en) 2000-07-28 2003-02-11 University Of Arizona Foundation Cancer treatment
US6645938B2 (en) 2000-10-10 2003-11-11 Zymogenetics, Inc. Protection against ischemia and reperfusion injury
US20040122091A1 (en) 2000-10-11 2004-06-24 Esperion Therapeutics, Inc. Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses
FR2816212A1 (fr) 2000-11-03 2002-05-10 Air Liquide Sante Int Utilisation de monoxyde de carbone (co) dans le traitement des inflammations du systeme cardiovasculaire
CA2442457A1 (en) 2001-03-30 2002-10-10 Roland Buelow Carbon monoxide generating compounds for treatment of vascular, inflammatory and immune disorders
NZ562962A (en) 2001-06-21 2009-08-28 Fritz H Bach Carbon monoxide improves outcomes in tissue and organ transplants and suppresses apoptosis
US8246969B2 (en) 2001-11-16 2012-08-21 Skinmedica, Inc. Compositions containing aromatic aldehydes and their use in treatments
US20030157154A1 (en) 2002-01-04 2003-08-21 Bryan Fuller Compositions containing hydroxy aromatic aldehydes and their use in treatments
US7968605B2 (en) 2002-02-04 2011-06-28 ALFAMA—Investigação e Desenvolvimento de Produtos Farmacêuticos, Lda. Methods for treating inflammatory disease by administering aldehydes and derivatives thereof
US20080026984A1 (en) 2002-02-04 2008-01-31 Alfama - Investigacao E Desenvolvimento De Productos Farmaceuticos Lda Methods for treating inflammatory disease by administering aldehydes and derivatives thereof
EA200401070A1 (ru) 2002-02-13 2005-02-24 Бет Изрейэл Диконисс Медикал Сентер, Инк. Способы лечения сосудистых заболеваний
US20040143025A1 (en) 2002-04-01 2004-07-22 Roland Buelow Carbon monoxide generating compunds for treatment of vascular, inflammatory and immune disorders
EA200401365A1 (ru) 2002-04-15 2005-04-28 Юниверсити Оф Питтсбург Оф Дзе Коммонвелт Систем Оф Хайер Эдьюкейшн Способы лечения илеуса
ITMI20020960A1 (it) 2002-05-07 2003-11-07 Univ Degli Studi Milano Aldeidi lineari poliinsature e loro derivati ad attivita' antiradicalica e antitumorale
HRP20041071A2 (en) 2002-05-17 2005-06-30 Yale University University of Pittsburgh of the Commonwealth Syste Methods of treating hepatitis
RS105304A (sr) 2002-06-05 2007-02-05 Yale University, Postupci za lečenje angiogeneze, rasta tumora i metastaze
JP4323271B2 (ja) 2002-09-27 2009-09-02 花王株式会社 バレロラクトン化合物及び香料組成物
WO2004043341A2 (en) 2002-11-07 2004-05-27 University Of Pittsburgh Of The Commonwealth System Of Higher Education Treatment for hemorrhagic shock
GB2395432B (en) 2002-11-20 2005-09-14 Northwick Park Inst For Medica Therapeutic delivery of carbon monoxide to extracorporeal and isolated organs
GB2395431A (en) 2002-11-20 2004-05-26 Northwick Park Inst For Medica Combination of a metal carbonyl compound and a guanylate cyclase stimulant or stabilizer for the therapeutic delivery of carbon monoxide
US20070207217A1 (en) 2003-02-03 2007-09-06 Alfama - Investigacao E Desenvolvimento De Productos Farmaceuticos Lda Method for treating a mammal by administration of a compound having the ability to release CO
US7670631B2 (en) 2003-03-12 2010-03-02 ALFAMA—Investigação e Desenvolvimento de Produtos Farmacêuticos, Lda. Method for the prevention of malaria infection of humans by hepatocyte growth factor antagonists
US7709534B2 (en) 2003-04-28 2010-05-04 University Of The West Indies Method of treating strongyloides infections and medicaments therefor
CA2534415A1 (en) 2003-08-04 2005-02-17 Northwick Park Institute For Medical Research Therapeutic delivery of carbon monoxide
CA2560525A1 (en) 2004-03-18 2005-09-29 The University Court Of The University Of Glasgow Immunosuppressive cytokine
EP1771540A4 (en) 2004-06-24 2007-09-12 Flexitral Inc NEW ALDEHYDE MOST AND THEIR DERIVATIVES
WO2007073225A1 (en) 2005-12-20 2007-06-28 Alfama - Investigação E Desenvolvimento De Produtos Farmacêuticos Lda. Molybdenum carbonyl complexes for treating rheumatoid arthritis and other inflammatory diseases
GB0601394D0 (en) 2006-01-24 2006-03-01 Hemocorm Ltd Therapeutic delivery of carbon monoxide
GB0613362D0 (en) 2006-07-05 2006-08-16 Hemocorm Ltd Therapeutic delivery of carbon monoxide
AU2007328549A1 (en) 2006-12-06 2008-06-12 Alfama - Investigacao E Desenvolvimento De Produtos Farmaceuticos Lda Methods for treating inflammatory disease by administering aldehydes and derivatives thereof
EP2148688A1 (en) 2007-04-24 2010-02-03 Alfama - Investigaçao e Desenvolvimento de Productos Farmaceuticos LDA. Treatment of infections by carbon monoxide
WO2009013612A1 (en) 2007-07-24 2009-01-29 Alfama - Investigação E Desenvolvimento De Produtos Farmacêuticos, Lda. Prevention of gastric ulcery by carbon monoxide

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004533427A (ja) * 2001-04-07 2004-11-04 ウニヴェルジテートスクリニクム シャリーテ 高度増殖細胞によって引き起こされる疾病の治療のための物質
JP2004532244A (ja) * 2001-05-15 2004-10-21 ノースウィック パーク インスティテュート フォー メディカル リサーチ 一酸化炭素の治療目的での放出
JP2005519928A (ja) * 2002-02-04 2005-07-07 ハース，ベルナー Ｃｏ放出能力を有する化合物の投与によって哺乳動物を治療する方法と、ｃｏ放出能力を有する化合物ならびにその医薬組成物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN6012036130; Ｒｏｂｅｒｔｏ　Ｍｏｔｔｅｒｌｉｎｉ　ｅｔ　ａｌ: Ｃｉｒｃｕｌａｔｉｏｎ　Ｒｅｓｅａｒｃｈ ９０（２）, 2002, ｐ．１-８ *

Also Published As

Publication number Publication date
EP1978952A2 (en) 2008-10-15
US20110015263A1 (en) 2011-01-20
CN101466372A (zh) 2009-06-24
US8389572B2 (en) 2013-03-05
GB0601394D0 (en) 2006-03-01
WO2007085806A3 (en) 2007-12-27
WO2007085806A2 (en) 2007-08-02

Similar Documents

Publication Publication Date Title
JP2009523841A (ja) 一酸化炭素の治療的供給
US20100105770A1 (en) Therapeutic delivery of carbon monoxide
JP4637304B2 (ja) 芳香族及び複素環の硝酸誘導体
JP3271788B2 (ja) 新規なトロンビン阻害剤類
CN100369891C (zh) Hif羟化酶抑制剂
ES2312012T3 (es) Nuevos compuestos de telurio y su uso como inmunomodulares.
JPH06509566A (ja) 超酸化物の不均斉変化に有効な触媒としての窒素含有−大環状リガンドのマンガン錯体
JPH11507646A (ja) 疾患の予防及び治療のための酸化防止剤として有用な合成触媒遊離基スカベンジャー
JP2011520931A (ja) ｛ｆ−１９｝標識ｌ−グルタミン酸及びｌ−グルタミン誘導体（ｉｉｉ）、それらの使用並びにそれらを得る方法
US20040229935A1 (en) Cytotoxic compounds
JP3457687B2 (ja) 白内障治療用薬剤
TW200407310A (en) Compounds
JPWO1996032101A1 (ja) 癌転移抑制剤
US20030130523A1 (en) Substituted chiral allosteric hemoglobin modifiers
MX2008014707A (es) Compuestos de rutenio ii.
EP1185526A1 (fr) Derives d' amonium quaternaire, leur procede de preparation et leur usage en pharmacie
JP2004502696A (ja) 癌治療用のルテニウム（ｉｉ）化合物
JP2018537515A (ja) フェンカンファミンのプロドラッグ
WO2020249120A1 (zh) 氨基硫醇类化合物作为脑神经或心脏保护剂的用途
CN108473449B (zh) 一种作为吲哚胺-2,3-双加氧酶抑制剂的砜脒及其制备方法和用途
JP2023103371A (ja) 新規の芳香族化合物
EP1317260A2 (en) Methods for treating tumors using sulfonyl compounds
BR112014029295B1 (pt) Ciclobutenos e ciclobutanos anfifílicos e composição farmacêutica que os compreende
JPS6165870A (ja) ピラゾールジオン誘導体及びその使用
CN116731305A (zh) 一种抗肿瘤大环内酯聚合物及其制备方法和应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20090302

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100122

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100122

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110111

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120710

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120924

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20121001

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130319